The Lancet. RheumatologyHumansArthritisPsoriaticInterleukin-23Antibodies
Time to lift the moratorium on IL-23 inhibitors for axial psoriatic arthritis.
Antonio Tonutti, Kerem Abacar, Tom Macleod, Carlo Selmi, Dennis McGonagle
Published: 202610.1016/S2665-9913(25)00287-5
Abstract
The disappointment stemming from IL-23 inhibition failure in axial spondyloarthritis has resulted in expert panels extrapolating these results to axial psoriatic arthritis, with recommendations against the use of IL-23 inhibitors in this setting. How…
Preview only. Read the full abstract at the source